WINT: מחיר למכירות Windtree Therapeutics

The Windtree Therapeutics (WINT) P/S ratio, as shown on this GURU.Markets chart, allows for a valuation of the business relative to revenue generated from developing drugs for cardiac and pulmonary pathologies, with the value reflecting the current figure. The company's growth relies on synergy with cardiac centers during drug testing. Low geopolitical risks ensure operational stability within Western legal frameworks.

For Windtree Therapeutics (WINT), whose heart failure therapy patents are losing value due to FDA failures, a market value analysis relative to revenue via the revenue multiple reveals a genuine valuation imbalance. The current value of is calculated as the ratio of market capitalization to annual revenue, allowing investors to determine if the company is overvalued amid a chronic shortage of R&D capital.